Feature

Nature Biotechnology 25, 1395 - 1402 (2007)
Corrected online: 8 April 2008 | doi:10.1038/nbt1207-1395



There is an Erratum (June 2008) associated with this Feature.

Antivirals become a broader enterprise

Jeffrey L Fox1

Small molecules have dominated antivirals for decades, but other approaches are needed and biologics could show the way.

Top
  1. Jeffrey L. Fox is a contributing writer for Nature Biotechnology.
* In the version of this article initially published, the name of a person quoted on p. 1399 was incorrect. The CSO of Replicor of Laval, QC, Canada, given as "Andrew Toussaint" should be "Andrew Vaillant." The error has been corrected in the HTML and PDF versions of the article.

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Both a ?magic bullet? and good aim are required to link public health interests and health care needs in HIV infection

Nature Medicine News and Views (01 Mar 2000)

Extra navigation

Search PubMed for

Open Innovation Challenges

naturejobs

More science jobs
Post a job for free

ADVERTISEMENT